摘要
目的提示临床高度关注非霍奇金淋巴瘤患者化疗的风险。方法临床药师对1例复发、难治的非霍奇金淋巴瘤患者化疗过程中可能出现的肿瘤溶解综合征、乙肝病毒激活情况、骨髓抑制、血栓形成风险、迟发性腹泻、急性及迟发性呕吐进行评估,并实施药学监护。结果患者化疗过程中未出现严重不良反应,顺利完成本周期治疗。结论临床应具有非霍奇金淋巴瘤患者化疗的风险意识,提高用药安全性。
Objective To prompt the clinical to pay high attention to chemotherapy in patients with non-Hodgldn＇s lymphoma risk. Methods The clinical pharmacists assessed a recurrence and refractory non-Hodgkin＇s lymphoma patient during chemotherapy, with the potential risks of tumor dissolve syndrome,activation of hepatitis B virus, bone marrow inhibition, thrombosis, delayed diarrhea, acute and late-occurred vomiting evaluation,and implementation of pharmaceutical care. Results The patient finished this cycle treatment with no serious adverse reactions during chemotherapy. Conclusion The clinical professionals should be aware of the risks in the process of chemotherapy for non-Hodgkin lymphoma patients and improve the chemotherapy drug safety.
出处
《中国药物警戒》
2012年第4期247-249,共3页
Chinese Journal of Pharmacovigilance
关键词
临床药师
非霍奇金淋巴瘤
评估
药学监护
clinical pharmacist
non-Hodgkin lymphoma
assess
pharmaceutical care
